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Abstract
Background The endocannabinoid (eCB) system, an endoge-
nous lipid signaling system, appears to be dysregulated in
depression. The role of endocannabinoids (eCBs) as potent
immunomodulators, together with the accumulating support
for a chronic low-grade inflammatory profile in depression,
suggests a compelling hypothesis for a fundamental impair-
ment in their intercommunication, in depression.
Objective We aim to review previous literature on individual
associations between the immune and eCB systems and de-
pression. It will focus on peripheral and central mechanisms of
crosstalk between the eCB and immune systems. A potential
dysregulation in this crosstalk will be discussed in the context
of depression.
Results Investigations largely report a hypoactivity of the
eCB system and increased inflammatory markers in individ-
uals with depression. Findings depict a multifaceted commu-
nication whereby immunocompetent and eCB-related cells
can both influence the suppression and enhancement of the
other’s activity in both the periphery and central nervous sys-
tem. A dysregulation of the eCB system, as seen in depres-
sion, appears to be associated with central and peripheral con-
centrations of inflammatory agents implicated in the patho-
physiology of this illness.
Conclusion The eCB and immune systems have been individ-
ually associated with and implicated in pathogenic mecha-
nisms of depression. Both systems tightly regulate the other’s
activity. As such, a dysregulation in this crosstalk has potential
to influence the onset and maintenance of this neuropsychiat-
ric illness. However, few studies have investigated both sys-
tems and depression conjointly. This review highlights the
demand to consider joint eCB-immune interactions in the
pathoetiology of depression.
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Introduction
An increasing number of pathways external to the brain
are gaining support in explaining the pathogenesis of
major depressive disorder (MDD). In particular, findings
suggest an involvement of immunedysregulation (Maes
et al. 1995a; Raison et al. 2006; Dantzer et al. 2008;
Dowlati et al. 2010; Zunszain et al. 2013) and alter-
ations of the endocannabinoid (eCB) signalling system
(Hillard and Liu 2014) in the onset and maintenance of
this mood disorder.
Resea r ch ha s suppor t ed the i nvo lvemen t o f
immunedysregulation and more specifically, a low-
grade inflammation, in depression (Berk et al. 2013).
Findings reveal heightened levels of inflammatory
markers present in the peripheral blood and cerebral
spinal fluid (CSF) of depressed individuals, compared
to healthy controls. The influences of this chronic in-
flammatory state have been implicated in virtually every
neuropathophysiologic abnormality associated with ma-
jor depression (Miller et al. 2009).
The involvement of the eCB system in MDD has been
suggested more recently. The eCB system is a homeostatic
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mechanism identified following the discovery of the main psy-
choactive constituent in marijuana, Δ9-tetrahydrocannabinol
(THC) (Gaoni and Mechoulam 1964). This system refers to
three main components: (1) the endogenous lipid trans-
mitters: endocannabinoids (eCBs) anandamide (AEA)
and 2-arachidonoylglycerol (2-AG) (Devane et al. 1992;
Mechoulam et al. 1995); (2) the target of these eCBs: G-
protein-coupled receptors, cannabinoid receptor type 1
(CB1R) and 2 (CB2R) (Matsuda et al. 1990; Munro
et al. 1993); and (3) enzymes involved in the synthesis,
namely N-acylphosphatidylethanolamine-hydolyzing
phospholipase D (NAPE-PLD) and diacylglycerol lipase
(DAGL) (Bisogno et al. 2003; Okamoto et al. 2004) and
degradation enzymes including fatty acid amide hydrolase
(FAAH) and monoacylglycerol lipase (MAGL) (Cravatt
et al. 1996; Karlsson et al. 1997). Generated from
membrane-bound glycerophospholipids (Wang and Ueda
2009), eCBs refer to the wide spectrum of lipid-derived
fatty acid structural analogues (Alexander and Kendall
2007) of which AEA and 2-AG are the best described
(Fig. 1). These naturally occurring cannabinoids present
similar psychoactive properties to THC. They act on both
receptors CB1R and CB2R. There is an increasing interest
into eCB-like molecules that converge on common cata-
bolic and metabolic pathways, notably non-cannabinoid
AEA structural analogues, palmitoylethanolamine and
oleoylethanolamine (Alexander and Kendall 2007).
Involvement of alternative targets, non-classical receptors,
such as peroxisome proliferator-activated receptor
(PPAR)-α and transient receptor potential cation channel
sub-family V member 1 (TRPV1), are also being investi-
gated. However, investigations into associations between
the aforementioned and depression are scarce. As such,
influences of 2-AG and AEA will make up the evidence
base for this discussion.
Interestingly, there is a clear divide in expression levels
between tissues, with CB1R being expressed most commonly
in the brain and CB2R principally located across an array of
immune cells in the periphery (Malfitano et al. 2014). CB1R
and CB2R have thus shown differential involvement in
neuromodulation and immunoregulation, respectively
(Castillo et al. 2012).
This review will focus on the possible associations
between the immune and eCB systems and depression,
both independently of each other and interdependently.
It will highlight pathophysiological changes associated
with chronic activation of the immune system that
may be mechanistically relevant in facilitating the path-
ogenesis and potentiation of this neuropsychiatric disor-
der. As such, individual involvement of eCB activity
and inflammation in depression will be outlined initially,
followed by an examination of the evidence relevant to
their intercommunication, in the context of depression.
The inflammatory model of depression
Recent meta-analyses provide prominent support for an asso-
ciation between immune dysfunction and depression. Patients
with MDD showed elevated levels of several inflammatory
signalling proteins, such as IL-6, IL-1, tumour necrosis
factor-alpha (TNF-α) and C-reactive protein (CRP), in both
serum and plasma (Howren et al. 2009; Dowlati et al. 2010).
Moreover, a dose-response relationship has been observed
between severity of symptoms and levels of pro-
inflammatory cytokines as measured in a population














phospholipid bilayer of the
cellular membrane. Both eCBs
bind to intracellular and
extracellular CB1R and CB2R.
Intracellular degradation of AEA
and 2-AG occurs when bound to
FAAH and MAGL, respectively.
Products of this are AA and either
glycerol, from 2-AG, or
ethanolamine, from AEA
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continuum from community-based individuals to those clini-
cally depressed (Howren et al. 2009). Furthermore, exogenous
administration of the pro-inflammatory cytokine interferon
(IFN)-α, a recommended immunotherapeutic treatment for
chronic hepatitis C viral infection, leads to the onset of depres-
sion in around 30 % of these patients (Asnis and De La Garza
2006). This is believed to be as a result of the increased in-
flammatory response (McNamara and Lotrich 2012). A close
relationship has also been reported between dose of IFN-α
and subsequent changes in mood (Baraldi et al. 2012).
Further support comes from reports depicting an increas-
ingly evident comorbidity between depression and inflamma-
tory conditions, particularly those of an autoimmune-nature
(Iseme et al. 2014). A study measuring the prevalence of co-
morbidity between the inflammatory disease, psoriasis and
depression, found that 40 % of individuals diagnosed score
positively for depressed mood and 27 % were diagnosed with
MDD (Zaher et al. 2010). Interestingly, in a subsequent inves-
tigation, etanercept, a biopharmaceutical with anti-
inflammatory properties, significantly reduced the depressive
symptomatology presented in the same patient group, inde-
pendently of any improvements in the condition (Tyring et al.
2006). Other anti-inflammatory drugs, including celecoxib (a
cyclooxygenase-2 inhibitor), minocycline and acetyl salicylic
acid, have been similarly effective as adjunctive therapies in
reducing depressive symptoms (Mendlewicz et al. 2006;
Soczynska et al. 2012; Maciel et al. 2013; Köhler et al.
2014). Interestingly, current psychotropic treatments have also
been seen to possess anti-inflammatory qualities, suggesting a
possible contribution of immunoregulation in their efficacy
(Maes et al. 1999; Cattaneo et al. 2013; Horowitz et al. 2014).
Microglia activation is one of the mechanisms by which
peripheral immune challenges can alter brain functioning
(Dantzer et al. 2008). Increased microglia cell activation in
the hippocampus and a concomitant increase in central
TNF-α levels have been observed upon a peripheral immune
challenge (Riazi et al. 2008). Similar results were obtained
following peripheral administration of IL-2 (Schneider et al.
2012). Alongside elevated peripheral concentrations of in-
flammatory markers, both preclinical and clinical studies in
depression elude to microglial activation. Investigations in-
volving animal models of depression delineate altered expres-
sion of microglial activation markers, as well as chronicity-
dependent fluctuations in microglial concentration in areas of
the brain associated with mood regulation (Hinwood et al.
2012; Wohleb et al. 2012; Couch et al. 2013; Kreisel et al.
2014). Additionally, a post-mortem study also observed sig-
nificant microgliosis in depressed suicide victims (Steiner
et al. 2008). Not all studies agreed, as a PET scan revealed
no significant differences in microglia activation in depressed
individuals (Hannestad et al. 2013). Interestingly, the recent
discovery of the central nervous system lymphatic system
sheds new light into the possible mechanisms that may be
involved in the pathogenesis of depression via neuroinflam-
mation (Louveau et al. 2015). Regardless of the mechanisms
responsible for the resulting increase in CNS inflammation
following peripheral inflammation, elevated inflammatory
markers within the CNS are a common finding in the patho-
physiology of depression (Levine et al. 1999; Raison et al.
2006, 2009; Howren et al. 2009; Miller et al. 2009; Dowlati
et al. 2010). Such unabated inflammation results in several
molecular cascades associated with alterations in neurotrans-
mitter metabolism and neuroendocrine function typically
present in depression (Bakunina et al. 2015).
Dysregulation of the endocannabinoid system
in depression
Preclinical findings
Receptors of the eCB system are widely distributed in regions
of the brain markedly involved in mood regulation and medi-
ate physiological systems associated with emotional reward,
cognition and response to stress, dysregulations in all of which
are frequently reported in individuals with major depression
(Gorzalka and Hill 2011; Hill et al. 2012a).
The eCB system exerts its neuromodulatory effects through
mediating short- and long-term forms of synaptic plasticity.
Primarily involved in retrograde signalling, eCBs are synthe-
sised and released post-synaptically in a neurotransmitter-de-
pendent, depolarisation-induced manner. Cannabinoid recep-
tors (CBR)s, principally located on axon terminals of gluta-
matergic and GABAergic neurons, are targeted by the endog-
enous ligands, instigating a cascade of chemical events that
inhibit influx of Ca2+ via voltage-gated calcium channels,
thereby discontinuing presynaptic release of neurotransmit-
ters. Essential in the control of spatiotemporal eCB signalling
is the intracellular enzymatic degradation of the eCBs in the
presynaptic terminals, thereby terminating eCB-induced sup-
pression of depolarisation. Key enzymes responsible for this
finalising step are FAAH and MAGL (Castillo et al. 2012).
A hypoactivity of the eCB system has been observed in
animal models of depression, where genetic manipulation
and pharmacological interventions have provided the greatest
insight into how behaviour may be affected by eCB signalling.
Disruption of the eCB system resulting from CB1R knockout
mice presented significant increases in depressive-like behav-
iour (Valverde and Torrens 2012). Similar results have been
replicated with pharmacological antagonism of CB1Rs,
resulting in a depressive-like phenotype (Beyer et al. 2010).
Reduction in depressive-like behaviour have also been report-
ed following FAAH inhibition (Vinod et al. 2012). Pioneering
work in this field, conducted by the Piomelli group, includes
the potent antidepressant-like effects elicited by a FAAH in-
hibitor, seemingly due to elevated levels of AEA, in the mouse
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models of depression, tail suspension and forced swim tests
(Gobbi et al. 2005). This effect was again replicated in the
chronic mild stress test in rats, while investigating the effect
of chronic treatment with a FAAH inhibitor, observing a sim-
ilar concomitant increase in AEA (Bortolato et al. 2007).
Furthermore, overexpression of CB2Rs in mice resulted in
resistance to depression following exposure to stressful situa-
tions compared to a control group (García-Gutiérrez et al.
2010). Antidepressant and anxiolytic effects ensued subse-
quent to intraperitoneal administration of a CB2R agonist,
and this was reversed with administration of a pharmacolog-
ical CB2R antagonist (Bahi et al. 2014).
Attenuation of eCB signalling is reported in chronic unpre-
dictable stress (CUS), a well-established animal model that
evokes a symptomatic profile similar to a human depressive
phenotype (Willner 2005). Consequential effects of CUS in
mice have delineated a decrease in CB1R function with
resulting impairment of eCB-mediated retrograde signalling
in the nucleus accumbens (Wang et al. 2010). Reduced eCB
signalling is further supported by a significant decrease in
levels of AEA in regions associated with behaviour, such as
the hippocampus, hypothalamus, amygdala and ventral stria-
tum (Hill et al. 2008a). Interestingly, despite previous reports
of diminished CB1R functioning, CUS produces a contradic-
tory increase in CB1R protein and mRNA expression in the
prefrontal cortex (PFC) (Hill et al. 2008a; McLauglin et al.
2013). This increase however is suggested to be a compensa-
tory effect of reduced eCB signalling as demonstrated by stud-
ies that reported decreased PFC AEA content (Hill et al.
2008a) and exacerbated depression following CB1R antago-
nist administration (McLauglin et al. 2013). Interestingly,
CB1R upregulation has been documented in post-mortem
studies of depressed individuals and depressed suicide victims
compared to controls (Hungund et al. 2004; Choi et al. 2012).
Of note is the widely investigated involvement of eCB
activity in the hypothalamic-pituitary-adrenal (HPA) axis.
Dysregulation of the HPA axis is a commonly observed attri-
bute of depression and has been implicated in its pathophys-
iology (Pariante and Lightman 2008; Zunszain et al. 2011).
Through tonic regulation of the HPA-axis, eCB activity, me-
diated via CB1Rs, is responsible for maintaining basal tone
(Hill and Tasker 2012b). Pharmacological blockade of the
CB1Rs disrupts this tonic regulation and results in increased
corticosterone levels (Patel et al. 2004; Wade et al. 2006).
Likewise, CB1R KO mice exhibited depressive-like symp-
toms and a concomitantly higher basal adrenocorticotropic-
releasing hormone level, in comparison to wild-type mice
(Barna et al. 2004).
Further indication of eCB dysregulation in the aetiology of
depression stems from its influence on hippocampal
neurogenesis. CB2R functionality has been implicated in all
key stages of neural progenitor cell cycle proliferation, differ-
entiation and migration (Palazuelos et al. 2012; Galve-Roperh
et al. 2013). Pharmacological blockade of CB1R suppressed
dentate gyrus progenitor proliferation and reduced brain de-
rived neurotrophic factor (BDNF) content in the hippocampus
(Lee et al. 2009; Beyer et al. 2010). The reverse is also true,
with increased stimulation of neurogenesis due to elevated
BDNF following increased eCB signalling (Jiang et al.
2005; Duman and Monteggia 2006; Wyrofsky et al. 2015).
It is important to consider that whilst the neurogenic theory of
depression is supported by promising results in preclinical
investigations, heterogeneity of clinical findings has provoked
scepticism. At present, measures of neurogenesis in the hu-
man population are indirect and improvements in methodolo-
gy are necessary to verify this hypothesis (Miller and Hen
2015). A reduction in hippocampal neuronal density resulted
from consistent use of marijuana, the occurring process sug-
gested to be mediated by the increased levels of THC
(Landfield et al. 1988). Persistent use of marijuana also led
to decreased CB1R expression (Hirvonen et al. 2012). Of
relevance to depression is the aforementioned neural atrophy
associated reductions in BDNF in the hippocampus, as this
feature has been observed in major depression and associated
animal models (Sheline et al. 1996; Santarelli et al. 2003; Lee
and Kim 2010).
Clinical findings
Clinical investigations of eCB-associated effects in the area of
depression are relatively sparse. Nonetheless, findings have,
for the most part, verified the eCB-depression association re-
ported in preclinical data. For example, rimonabant, a CB1R
antagonist developed for use as an anti-obesity drug, was
withdrawn from the market due to serious adverse effects on
mood that resulted in the onset of depression and suicidal
ideation (Topol et al. 2010). Several other pharmaceuticals,
namely taranabant, otenabant, ibipinabant and surinabant, also
CBR antagonists, were removed earlier on, during clinical
trials, for similar reasons (Wyrofsky et al. 2015). Moreover,
abnormally reduced levels of ethanolamine, a precursor and
metabolite of AEA, are present in the CSF of a significant
proportion of individuals diagnosed with MDD, compared
to healthy controls (Ogawa et al. 2015). Comparable reduc-
tions in circulating levels of 2-AG have been found in de-
pressed patients compared to controls, which progressively
decreased over the duration of the disorder (Hill et al.
2008b). Furthermore, associations have been found between
gene polymorphisms in CNR1, CNR2 (genes coding for
CB1R and CB2R, respectively) and FAAH genes and behav-
iours characteristic of depression (Zajkowska et al. 2014).
However, due to the promiscuous involvement of eCB activ-
ity in numerous physiological pathways, it is important to
acknowledge the great number of confounding factors, in clin-
ical investigations of an eCB-depression association.
Variances in eCB concentrations can arise from a multitude
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of lifestyle modifications such as exercise, diet and changes in
weight as well as intake of tobacco, coffee, alcohol and can-
nabis. Use of pharmaceuticals is also known to influence fluc-
tuations in eCB levels. Most critically, the use of anti-depres-
sants, anti-psychotics and anxiolytics can upregulate the eCB
system (McPartland et al. 2014).
Crosstalk and dysregulation in the periphery
Current research delineates a complex bidirectional interac-
tion between the peripheral eCB and immune systems, where
circulating eCBs are not only affected by the immune system
but also mediate transient effects on the immune response.
Predominantly, CB2Rs and, to a lesser extent, CB1Rs are
expressed with high and varying degrees of prevalence across
the spectrum of haematopoietic cells, with B cells having the
highest expression and CD4 Tcells the lowest (Malfitano et al.
2014). Mechanisms that underlie eCB-mediated effects can
manifest directly through communication with immune cells
or indirectly via modulation of eicosanoid signalling (Rouzer
and Marnett 2011). Both pathways utilise molecular cascades
to manipulate activation, proliferation, secretion and apopto-
sis, with eventual immunoregulatory and inflammatory out-
comes. Moreover, immune cells also contribute to coordinat-
ing eCB signalling through regulation of transcription, syn-
thesis, uptake and degradation of eCB components (Pandey
et al. 2009).
Influences of eCB signalling on the immune system
Evidence suggests an involvement of eCB signalling primar-
ily in immunosuppression. For instance, CB2R activation has
been shown to attenuate inflammation in a range of inflam-
matory conditions from injury, inflammatory pain, hepatic
injury and intestinal inflammatory disorders (Pandey et al.
2009). Furthermore, levels of circulating protein and mRNA
encoding for IL-1, IL-6 and TNF-α are reduced by the admin-
istration of synthetic cannabinoids in a preclinical model of
multiple sclerosis (MS) treatment (Croxford and Miller 2003).
Furthermore, in an animal model of autoimmune hepatitis,
Concanavalin (Con)A-induced acute hepatitis, administration
of AEA has been shown to diminish hepatic injury, and this is
correlated with a significant reduction in inflammatory cyto-
kines such as TNF-α, IL-1B, IL-6, IL-9 and IL-17. The ther-
apeutic effects of AEA are CB1 and CB2 dependent, as block-
ade of the receptors independently ameliorate the immunosup-
pressive effects (Hegde et al. 2008). However, a recent study
suggests that this effect is not limited to CBR activity.
Cannabidiol (CBD) is another component in marijuana; whilst
it displays low affinity for CBRs, it possesses an affinity with
TRPV1. CBD reduces inflammatory cytokines TNF-α, IL-2,
IL-6, IL-12 and IL-17 in ConA treated mice, but this is
inhibited in TPRV1 knockout (KO) mice (Hegde et al.
2011). Interestingly, the inflammatory effects exhibited in this
disorder, and its preclinical model, are specifically mediated
by the polyclonal activation of T cells. Hence, findings from
these studies may support evidence for the expanding litera-
ture detailing eCB influences on inflammation through medi-
ating suppression of T cell proliferation. In accordance, the
eCB system is heavily implicated in regulating activation
and subsequent proliferation of the lymphocytes, B cells and
T cells. Evidence suggests a possible role of tonic eCB signal-
ling that may provide an inhibitory control over spontaneous
immune activation of lymphoid tissues (Pandey et al. 2009).
CBRs and eCB ligands are collectively involved in the sup-
pression of adenylate cyclase (AC) activity and by extension,
cyclic adenosine monophosphate (cAMP) regulation.
Lymphocyte activation requires stimulation of the cAMP sig-
nalling pathway; consequently, eCB intervention may coun-
teract this process (Pandey et al. 2009). For example, AEA
suppresses human T lymphocyte proliferation and this is de-
pendent on CB2R action, as shown by replication of the afore-
mentioned effect by administration of CB2R agonist and ame-
lioration following use of a CB2R antagonist (Cencioni et al.
2010). A similar result has been demonstrated with 2-AG in
mouse splenocytes, where the ligand produces a marked dose-
dependent inhibition of anti-CD3 mAb-induced T cell prolif-
eration and lipopolysaccharide (LPS)-induced B cell prolifer-
ation (Lee et al. 1995).
Therefore, application of this knowledge to reports of eCB
hypoactivity in depressed individuals elicits expectation of
findings depicting associated increases in lymphocyte concen-
trations. Surprisingly, the opposite is largely described in the
literature, with reports of reduced T cell concentration in pe-
ripheral bloods of depressed patients compared to controls
(Maes et al. 1995b; Zorrilla et al. 2001; Irwin and Miller
2007). However, research has yet to clearly map species-
specific interactions of eCB signalling on divisions within
the T cell taxonomy. Elucidation of pathways associated with
non-classical receptor activation within lymphocytes is also
required. Future avenues of research must work to address
these issues in order understand eCB-mediated effects on lym-
phocyte activity in the context of depression.
Eicosanoid signalling in eCB-mediated effects
on the immune system
In part, eicosanoid signalling facilitates the intercommunica-
tion between eCB signalling and immunoregulation.
Eicosanoids are bioactive molecules that exert a complex con-
trol over many homeostatic functions within the body; of rel-
evance is their influence on inflammation. Biosynthesis of
eicosanoids initially requires oxidation of the polyunsaturated
fatty acid, arachidonic acid (AA), by the enzymes cyclooxy-
genase (COX) and lipoxygenase (LOX). Prostaglandins such
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as prostaglandin E2 (PGE2) or leukotrienes are metabolised by
COX and LOX, respectively (Alhouayek et al. 2014). Both 2-
AG and AEA are derivatives of AA, making them subject to
the same oxidative metabolic pathways key to eicosanoid bio-
synthesis (Fig. 2). By extension, fluctuations in eCB signal-
ling can impact eicosanoid signalling. As a result, eicosanoids
provide a collateral method of eCB-mediated control of im-
mune functioning (Rouzer and Marnett 2011). For example,
an analogue of CBD, HU-308, a CB2R agonist that binds with
high specificity, exhibits a significant anti-inflammatory effect
in mice with AA-induced ear edema. Subsequent CB2R an-
tagonist administration reverses this immunosuppression
(Hanus et al. 1999; Burstein 2015). In another study, LPS-
induced IL-6 production was decreased by THC, indometha-
cin morpholinylamide (IMMA), AEA and 2-AG in a dose-
dependent manner. Interestingly, despite previously described
anti-inflammatory properties of eCBs, both AEA and 2-AG
did not inhibit COX-2 production of PGE2; moreover, 2-AG,
contrary to THC, IMMA and AEA, caused a subsequent in-
crease in iNOS-dependent NO (itself an inflammatory agent)
production, thus providing an immunoenhancing effect.
Discrepancies within the results seen in 2-AG, PGE2 and
NO production were understood to be the result of increased
metabolic degradation of 2-AG to AA, which in turn served as
a substrate for catalysing increased COX-2 production of
PGE2, known to potentiate NO production (Chang et al.
2001). This study demonstrates that inflammation is a con-
stant balance between pro-inflammatory and anti-
inflammatory substances and eCB and eicosanoid signalling
play homeostatic roles in its regulation.
An alternative pathway of enzymatic oxidation of AA by
LOX provides immunosuppressing properties that mitigate
those observed by COX-produced metabolites. N-
arachindonoylglycine, another endogenous eicosanoid, is an
AEA metabolite (Bradshaw et al. 2009). This cannabinoid
analogue has anti-inflammatory effects, probably thanks to
its ability to promote the release of AA, successively increas-
ing LOX-catalysis of AA to lipoxin A4 (LXA4) (Burstein
et al. 2011). Increased concentrations of LXA4 are associated
with the resolution phase of an acute inflammatory response,
in which it induces inflammatory cell apoptosis (Bannenberg
and Serhan 2010). Given the elevated inflammatory profile
observed in depression and the immunoregulating properties
of lipoxins and their relationship with eCBs, it would be in-
teresting to explore a potential association between depression
and lipoxins. No study to date has directly investigated this
avenue of research.
Interestingly, PGE2 has been implicated in depression.
Elevated levels of PGE2 in plasma, serum and saliva have
been measured in patients with MDD (Lieb et al. 1983;
Ohishi et al. 1988; Song et al. 1998). PGE2 has been demon-
strated in inflammatory conditions to upregulate
phosphodiesterase-4 (Oger et al. 2015), which in turn inhibits
downstream formation of BDNF (Logan 2003), which itself is
implicated in depression.
Influences of immunocompetent cells on eCB signalling
Biochemical evidence also suggests the immune system plays
a profound role in the regulation of eCB signalling. Immune
stimuli, such as LPS, have demonstrated that immune cell
activation can also modulate eCB signalling by increasing
expression of CBRs (Klein et al. 2003). Of relevance, lym-
phoid CBR and AEA are also elevated in patients suffering
fromMS, where pro-inflammatory cytokines are a pathogenic
component of the disease (Sospedra and Martin 2005); fol-
lowing 1 year of treatment with the anti-inflammatory IFN-β,
levels of AEA and expression of CBR progressively decrease
(López et al. 2014).
Elucidation of underlying mechanisms in immunocompe-
tent cells demonstrates an endogenous control and modulation
over key stages in eCB functioning. A preclinical study of
murine macrophages demonstrates their capacity to produce
both AEA and 2-AG, intriguingly through differential path-
ways. AEA synthesis was observed to be dependent on LPS-
induced transcription of proteins either directly responsible for
the synthesis of AEA or involved in the activation of proteins
responsible for the synthesis of AEA. NF-кB appeared to be a
key signalling molecule in the LPS-induced transcriptional
pathways. In contrast, LPS-induced increases in platelet-
activating factor (PAF) are the primary intermediate of 2-AG
synthesis in macrophages, dependent on PAF receptor activa-
tion (Liu et al. 2003).
Immune cells are also involved in termination of eCB sig-








Fig. 2 Eicosanoids, PGEs and leukotrienes, can bemetabolised from two
differential eCB-related pathways. 2-AG and AEA can be metabolised
directly into either PGEs or leukotrienes by COX and LOX, respectively.
Alternatively, degradation of eCBs can occur via enzymes, either MAGL
or FAAH, into AA, which is subsequently oxidised by COX and LOX to
produce PGEs and leukotrienes, respectively. Therefore, fluctuations in
eCB concentration can influence eicosanoid levels
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AG. AEA in vitro has been shown to accumulate in
peripheral immune cells in a concentration-dependent
manner (Hillard and Jarrahian 2003). Following LPS
administration, increased peripheral lymphatic AEA
levels are seen, probably as the result of reduced
FAAH expression, thus demonstrating the presence of
degradative enzymes within human peripheral lympho-
cytes (Maccarrone et al. 2001).
Crosstalk between the eCB and immune systems
in the CNS
Peripheral eCB signalling can be reflected in the brain through
transportation of eCBs across the blood-brain barrier (BBB)
via endothelial cell membranes of brain microvessels. Studies
report a differential expression of CB1R and CB2R on the
luminal and abluminal membranes, respectively, as well as
opposing function: CB1R increases NO production and thus
augments AEA membrane transporter (AMT) activity, and
CB2R supresses AMT activity by negating NO production
(Maccarrone et al. 2005). Taken together, these findings indi-
cate a possible unidirectional transportation of AEA across the
BBB (Centonze et al. 2008) (Fig. 3). A similar neuroprotec-
tive role has been observed following administration of two
highly selective CB2R agonists, which reduce TNF-α-
induced upregulation of several genes within the primary hu-
man brain microvascular endothelial cells that constitute the
BBB. Using functional assays, CB2R stimulation results in
BBB protection proceeding inflammatory insult and dimin-
ished monocyte migration across the BBB (Persidsky et al.
2015).
Whilst the presence of CB1Rs in the CNS has been well
characterised, the role and expression of CB2Rs has been the
object of controversy. However, recent understanding of
methodological flaws in detecting CB2R expression in the
CNS has improved current methods of detection. As such
supporting evidence has been on the rise. Since identifying
the presence of CBRs on immunocompetent cells within the
CNS, implications of intercommunication between the eCB
and immune systems have become increasingly prominent.
Microglia, the resident immune cells of the CNS, is of partic-
ular relevance due to their considerable neuroimmune regula-
tory properties. CB1Rs are located on microglia, neuronal
terminals and astrocytes, with CB2Rs largely expressed in
microglial as well as glial cells (Stella 2010). Moreover,
microglial cells are not only the primary source and target
for inflammatory mediators (Czirr and Wyss-coray 2012)
but cultured astrocytes and microglia are also capable of 2-
AG and AEA production (Stella 2009). Chronically activated
microglial cells have been increasingly associated with neuro-
degenerative disorders and neuroinflammatory progression
(Streit et al. 2004). Likewise, upregulation of CB2Rs has been
found in activated microglia and in neuroinflammatory disor-
ders, such as MS, motor neurone disease, Down syndrome
and Alzheimer’s disease (Rom and Persidsky 2013). Such a
coexisting dysregulation observed in both systems suggests an
underlying communication and implicates potential impair-
ment of its interaction in neurological disorders where inflam-
mation is central to its pathogenesis, a feature now growing in
recognition as relevant to depression.
Influences of eCB signalling on the immune system
Through use of CB2R agonists and transgenic mice,
CB2Rs have been described as proficient neuroprotective
mediators and are involved in reduced BBB endothelial










Fig. 3 Differential expression of CB1R and CB2R on the luminal and
abluminal membranes, respectively, may lead to unidirectional transport
of AEA. CB1R increases nitric oxide (NO) production, which in turn
induces activity of a selective AEA membrane transporter (AMT).
Increased levels of AEA are then transported across the BBB. CB2R
negates NO production and therefore suppresses AMT activity. Thus,
transport of abluminal AEA across the BBB is reduced
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ruiz et al. 2006). Their role in neuroinflammation has
been characterised as largely suppressive, consistent with
notions of neuroprotective properties, through actions
that directly alter the balance of pro-inflammatory and
anti-inflammatory mediators (Rom and Persidsky 2013).
In accordance, recent studies have established a predom-
inantly anti-inflammatory effect of microglial CB2R
stimulation (Fernández-ruiz et al. 2006). In vitro and
in vivo studies report similar findings of cannabinoid-
induced increases in glial cell secretion of the anti-
inflammatory cytokines IL-4 and IL-10 (Molina-
Holgado et al. 1998). Successive investigation also found
that CB2R signalling inhibits IFN-γ-induced mouse
microglial cell expression of the pro-inflammatory medi-
ators, iNOS and CCR2, a gene encoding for a receptor
associated with monocyte infiltration (Racz et al. 2008).
Two states of microglial cell activation are documented,
a classic activated state (M1) and the alternative state
(M2) (Cherry et al. 2014). M1 polarisation is associated
with cytotoxic pro-inflammatory secretion of TNF-α, IL-
1β and IL-6, whereas M2 is considered to have anti-
inflammatory and neurotrophic properties, releasing IL-
10 and BDNF (Ma et al. 2015). Recent indications of a
CB2R role in mediating a shift from M1 state to M2
have been described. Following pretreatment with the
CB2R agonist AM1241, inflammation is attenuated, with
a concomitant enhanced release of anti-inflammatory and
neurotrophic factors. Moreover, expression of iNOS, a
marker for M1 activity, decreases, whilst expression of
M2 marker, Arg-1, increases. AM1241 effects are ame-
liorated after administration of CB2R antagonist and pro-
tein kinase C (PKC) inhibitor, indicating firstly that the
effects are CB2R mediated but also that PKC activity
may facilitate the effects (Ma et al. 2015). Such results
support the immunosuppressive observations seen of
CB2R activation in the brain. Similarly, exogenous 2-
AG administration in acute experimental autoimmune en-
cephalomyelitis, a preclinical model, produces increased
microglia population as well as M2 shifting. A recent
mechanism proposed by Nakagawa and Chiba (2014)
alludes to a differential immunomodulatory action of 2-
AG dependent on the state of microglial activation and
CBR. 2-AG binding to CB1R in M1-activated state mi-
croglia results in increased proinflammatory mediators,
whereas 2-AG binding to CB2R on M2-polarised mi-
croglia elevates the anti-inflammatory cytokine IL-10
and the proresolving factor lipoxin A4 (Nakagawa and
Chiba 2014) (Fig. 4). Further examination into the influ-
ences of the eCB system on microglial polarisation need
to be carried out in order to provide a more comprehen-
sive support.
Impaired functionality of 2-AG-CB2R binding may
contribute, in part, to the onset of depression. A study
of note, conducted by Onaivi et al. (2008), found that a
particular polymorphism (Q63R) of the CB2R gene is of
significantly higher incidence in Japanese depressed pa-
tients than controls. Interestingly, this polymorphism has
been shown to compromise the activation of the receptor
in mice, with reports that 2-AG binding with CB2-Q63R
produce significantly lesser maximum responses than in
wild-type mice (Carrasquer et al. 2010). Additionally,
chronic administration of minocycline, which has anti-
inflammatory action, attenuates depressive-like behav-
iours in the olfactory bulbectomised animal model of
depression. It also shows a concomitant downregulation
of CD11, a marker of M1 activation, increased expres-
sion of the M2 microglia state marker, MRC2, and a
shift from pro-inflammatory to anti-inflammatory cyto-
kines (Burke et al. 2014). Taken together, the aforemen-
tioned evidence provides support for the hypothesis of
impaired M2 polarisation in individuals suffering with
depression, possibly due to reduced 2-AG-CB2R bind-
ing. Nonetheless, more research is needed to determine
the effects of various eCB-CBR binding on microglial
secretion of inflammatory markers, in the context of de-
pression. Further to this, despite substantial evidence to
support the dynamic plasticity in microglial function, on-
ly two studies, to date, have investigated an associated
microglia polarisation skew in depression. More critical-
ly, reported findings were contradictory (Hannestad et al.
2013; Burke et al. 2014). However, a recent compelling
study reported significant anti-inflammatory effects of
commonly prescribed antidepressants, fluoxetine and
escitalopram, mediated by a shift from M1 microglia
polarisation to M2 alternative state activation (Su et al.
2015). This suggests the efficacy of these therapeutic
interventions may, in part, be attributable to altered
microglial plasticity. Further investigation is greatly war-
ranted in order to ascertain the implications posed, by
evidence of microglia polarisation, to our understanding
of the pathophysiology underlying depression.
Additional implications of 2-AG in the suppression
of neuroinflammation are supported by the observation
that 2-AG, as well as AEA, suppresses LPS-induced
TNF-α secretion by microglial cells (Facchinetti et al.
2003). Microglial cells secrete 2-AG in response to el-
evated neuroinflammation caused by injury (Panikashvili
et al. 2001; Stella 2004). Furthermore, 2-AG increases
microglial cell proliferation in a CB2R-dependent manner
(Carrier et al. 2004).
Interestingly, the eicosanoid system seems to be im-
plicated in CNS endocannabinoid immune-related
communication. Increases in 2-AG and attenuation of
free AA concentrations have been reported in mice
treated with the MAGL inhibitor, JZL184 (Long
et al. 2009). Genetic and pharmacological inhibition
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of MAGL in LPS administered mice resulted in re-
duced prostaglandins PGE2, PGD2, PGF2a as well as
pro-inflammatory cytokines IL-1α, IL-1β, IL-6 and
TNF-α in the brain, despite LPS administration.
Consistent with the notion of eicosanoid involvement,
these immunosuppressive effects are replicated by
COX-1 blockade but are not reversed by a CB1R antagonist








Fig. 4 Differential binding of 2-AG to CBRs on microglia elicits differ-
ential immunomodulatory effects, dependent on the state of microglial
activation. Binding of CB2R on M2 state microglia is associated with
increased concentrations of anti-inflammatory agents. CB2R-2AG
binding inhibits IFN-γ-induced microglial cell expression of proinflam-
matory agents. 2-AG binding to CB1R in M1-activated state microglia,

















Fig. 5 Peripheral: eCB action on
CB2Rs results in suppression of
immune cell activation by
inhibiting AC conversion of
adenosine tri-phosphate (ATP) to
cAMP. eCBs can be metabolised
in to arachidonic acid (AA) which
can subsequently be converted to
inflammatory molecule,
prostaglandins (PGE), or anti-
inflammatory agent, leukotrienes
(LOX) CNS: 2-AG induces M2-
state microglia to secrete anti-
inflammatory agents; BDNF,
LXA4 and IL-10, mediated by
CB2Rs
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Influences of the immune system on eCB signalling
The communication in the CNS, as in the periphery, is
bidirectional, and extensive research has demonstrated
not only effects of the eCB system on immunomodulation
but also immunoregulatory effects of the immune system
on eCB signalling. For example, upon LPS administra-
tion, CB1R expression is significantly reduced, probably
due to reduced CB1R protein (Hsieh et al. 1999). In par-
ticular, CB1R immunoreactivity is diminished in the hip-
pocampus and dorsal bed nucleus of the terminal stria
terminalis in mice, areas associated with major depression
and stress/reward pathways. However, CB1R mRNA is in-
creased after LPS administration, indicating inflammation-in-
duced adaptive regulation at the protein level as op-
posed to transcriptional dysregulation (Hu et al. 2012).
The same study reported that LPS decreases expression
of CB1R in CA3 pyramidal layer glutamatergic nerve
terminals of the hippocampus. These findings may indi-
cate a reduction in CB1R dependent suppression of glu-
tamatergic synaptic transmission. Such overactivation of
glutamatergic pathways can result in increased excitoxic
damage and subsequent hippocampal atrophy, changes
that have associations with mood disorders (Jorge
et al. 2007; Zunszain et al. 2011).
Concluding remarks
This nascent field of research implicates an intricate in-
tercommunication between the peripheral and central
eCB and immune systems in the pathogenesis of depres-
sion. Findings depict a multifaceted communication
whereby immunocompetent and eCB-related cells can
both influence the suppression and enhancement of the
other’s activity. Typical functioning of the peripheral
eCB system involves a tonic signalling control over
spontaneous immune cell activation, mediated by cAMP
pathways, thereby suppressing an inflammatory response.
Similarly, eCB interactions with neural constituents pro-
vide key neuroprotective effects, suggested to be, in part,
due to increased anti-inflammatory microglial M2-state
cells through 2-AG-CB2R functioning. Moreover, an
interaction with the eicosanoid signalling system influ-
ences the balance of pro- and anti-inflammatory agents:
prostaglandin and leukotrienes, respectively. By exten-
sion, dysfunction of the eCB system has potential to
chronically activate the inflammatory response and ex-
acerbate neurodegeneration, both characteristics fre-
quently observed in depression (Fig. 5).
Comprehensive understanding of the biochemistry
that manifests with depression warrants clarification on
the impact of cell type, concentration and cellular
environment and receptor density on eCB-immune pro-
cessing. Elucidation of these factors will increase the
potential for effectual therapeutic intervention towards
a more personalised approach.
Summary
• Inflammatory component in depression
- Elevated levels of inflammatory signalling proteins in plasma and
serum taken from individuals with depression
- Increased inflammatory markers within the CNS
- Altered microglial activity in preclinical and clinical studies of
depression
- Associated changes in inflammation with typically reported
abnormalities in physiological processes implicated in depression;
neurotransmitter metabolism, neuroendocrine function and
neuroprogression
• Role of the endocannabinoid (eCB) system in depression
- Reported hypoactivity of the eCB system in animal models of
depression
- Manipulation of the eCB system results in associated changes in
depressive-like behaviour in preclinical studies
- HPA axis dysregulation, a commonly documented attribute of
depression, can be produced by alterations of the eCB system
- eCB system is implicated in stages of neurogenesis
• Peripheral crosstalk and dysregulation of the eCB-immune system and
its associations with depression
- eCB activity is involved in immunosuppression through tonic
regulation of cAMP production
- 2-AG and AEA (eCBs) can be metabolised to produce eicosanoids.
Dependent on the degradative enzyme, inflammatory or anti-
inflammatory molecules, PGE or LOX, respectively, are produced
- Abnormal concentrations of PGE2 have been associated with
depression
- Activated immune cellsmodulate eCB levels through their production,
uptake and degradation
- Central crosstalk and dysregulation of the eCB-immune system and its
associations with depression
- eCBs are largely neuroprotective, due to their suppression of
neuroinflammation
- Suppression of neuroinflammation is suggested to be the result of eCB
influences on microglial state polarisation.
- Possible association between reduced 2-AG-CB2R binding on M2
(alternative state microglia) and depression
- Immune insult to the CNS alters levels of CB1R expression in areas
associated with major depression
- Reduced CB1R expression can lead to hippocampal atrophy, a feature
reported in mood disorders.
• Future directions
Peripheral focus
- Studies that address depression and eCB and immune system
crosstalk, conjointly, both in the periphery and CNS
- Clarification of eCB and lymphocyte interaction, in the context of
depression
- Outline specific interactions of eCB signalling with different species
included in the T cell taxonomy.
- Elucidate potential disparities in pathways associated with non-
classical receptor activation of lymphocytes.
- Further study of eicosanoid, in particular lipoxin, concentrations in
individuals with depression
CNS focus
- Further examination into influences of the eCB system on microglial
polarisation
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- Investigations into an association between microglial polarisation state
and depression
- Effects of various eCB-CBR binding on microglia secretion of inflam-
matory markers and whether this effect is associated with depression.
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